Drug-drug interactions play an important role in the discovery and development of therapeutic agents. High-content profiling was developed to unravel the complexity of these interactions by providing multiparameter measurements of target activity at the cellular and subcellular levels. Two microtubule drugs, vinblastine and curacin A, were shown to modulate multiple cellular processes, including nuclear condensation, the activation of the extracellular signal-regulated kinase pathway as measured by RSK90 phosphorylation, and the regulation of the microtubule cytoskeleton as measured in detergent-extracted cells. The heterogeneity of the response, addressed through population analysis and multiparameter comparisons within single cells, was consistent with vinblastine and curacin A having similar effects on nuclear morphology and 90 kDa ribosomal s6 kinase (RSK90) phosphorylation despite having distinct effects on the microtubule cytoskeleton. Ketoconazole, originally developed as an antifungal agent, exhibited concentration-dependent inhibitory and potentiating effects on both drugs in HeLa and PC-3 cells at concentration ranges near the plasma levels of ketoconazole attained in human subjects. Thus, high-content profiling was used to dissect the cellular and molecular responses to interacting drugs and is therefore a potentially important tool in the selection, characterization, and optimization of lead therapeutic compounds. (Journal of Biomolecular Screening 2003:125-135) 
INTRODUCTION
E VALUATING DRUG-DRUG INTERACTIONS has become an important part of any drug discovery program. Successful clinical treatment strategies seek to augment the potentiation of desirable effects and minimize deleterious activities. Genomics and proteomics are rapidly expanding their contributions to many cancer treatment approaches, including those involving drug-drug interactions. Examples of tumor classification using gene expression arrays 1 and protein arrays 2 continue to appear. Furthermore, cellular gene expression profiles in response to drug treatment are also now available. 3 Nonetheless, cataloging cellular responses in terms of the complex network of chemical and molecular pathways that anticancer drugs modulate has become one of the most challenging problems in biomedicine. In one approach to building this catalog, 60 tumor cell lines have been assembled into a panel, described morphologically and immunocytochemically, 4 and screened for the growth inhibitory action of anticancer drugs 5 as well as cytochrome P450 enzyme expression patterns. 6 Highcontent profiling was designed to extend genomic, proteomic, and other cell-based cataloging approaches by providing a combinatorial cell biological context in which to profile drug effects on the temporal and spatial distribution of cellular ions, metabolites, macromolecules, and organelles.
In normally cycling cells, for example, several lines of recent evidence support the hypothesis that mitotically activated cell stress pathways are interconnected with the regulation of the microtubule cytoskeleton. For example, inhibition of the mitogenactivated protein kinase (MAPK) pathway in Xenopus egg extracts terminates mitosis and interferes with the production of normal mitotic microtubules. 7 When genetic manipulation methods are used to interfere with the cytoplasm to nuclear translocation of p42/p44 MAPK, the phosphorylation of MAPK targets, including 90 kDa ribosomal s6 kinase (RSK90), is inhibited, and cell cycle progression is prevented. 8 When cell cycle synchronization meth-ods are used to produce more homogeneous cell populations, the activation of multiple stress pathways is induced at the G2/M transition in tumor cells 9 and fibroblasts. 10 Furthermore, the interaction of extracellular signal-regulated kinase kinase (MEK), extracellular signal-regulated kinase (ERK), and RSK90 with mitotic microtubules is required to exit normal mitosis in mouse fibroblasts. 11 Therefore, probing the mechanism of action of microtubule drugs, which are designed to target the molecular machinery of mitosis, in anticancer research has become a daunting challenge. Evidence consistent with the proposition that these drugs modulate myriad molecular and cellular processes beyond disrupting the microtubule cytoskeleton is continually mounting.
Individual experiments involving multiple microtubule drugs, cell types, target activities, and treatment protocols are producing an ever expanding collection of data, but combinatorial approaches to generate large arrays of cellular data on a single platform have yet to be explored. Such a platform would be used to define more precisely the mechanisms of drug action by defining the interrelationships between the myriad biological events that drugs potentially modulate. Reports involving microtubule drugs, including paclitaxel, [12] [13] [14] [15] vinblastine, 9, 16 nocodazole, 17 and colchicine, 18 as well as multiple drugs [19] [20] [21] [22] are consistent with interrelationships between the disruption of the mitotic microtubule cytoskeleton, the 3 stress kinase cascades (stress-activated protein kinase/c-jun NH2terminal kinase [SAPK/JNK], p38 MAPK, and ERK), and the induction of apoptosis. The ability to test the hypothesis that the effects of microtubule drugs are a direct consequence of their modulation of the microtubule cytoskeleton, some other target interaction, or a combination of both relies on the development of approaches designed to measure the temporal and spatial response of ions, metabolites, macromolecules, and organelles to single drugs or drug combinations.
Drug-drug interactions not only complicate the pursuit of the mechanisms involved in microtubule drug action but also may confound or impede chemotherapeutic strategy. Ketoconazole, developed originally as an antifungal drug, 23 plays a key role in one of the classic models of drug-drug interaction. Ketoconazole was first characterized as an inhibitor of ergosterol biosynthesis, which led to altered membrane permeability in yeast. 24 Ketoconazole was later found to have significant effects on mammalian cells based on a mechanism of action that included inhibition of adrenocorticotropin hormone (ACTH)-stimulated steroidogenesis in cultured adrenal cortex tumor cells. 25, 26 Indeed, some of the first deleterious side effects of the drug included hepatitis 27, 28 and endocrine effects showing that the drug reduced serum testosterone, 29 possibly leading to adrenal insufficiency. 30 The early evidence consistent with ketoconazole reducing serum testosterone levels in humans suggested that the drug might be useful in the treatment of hormone-sensitive diseases such as prostate cancer. Thus, the anticancer activity of ketoconazole was explored as single-drug therapy for prostate cancer 29 or in combination with other drugs such as gallium nitrate, 31 vitamin D, 32 or microtubule drugs. 33 The drug-drug interactions of ketoconazole, as applied to cancer chemotherapy, have evolved into a complex scenario, with the imidazole-based drug playing one role as a cytochrome P450 3A enzyme inhibitor, thereby modulating the activities of other drugs by preventing their biotransformation within the body. [34] [35] [36] [37] In another role, ketoconazole is viewed as an inhibitor of the drug resistance proteins that many cells possess. 38, 39 Finally, ketoconazole is also believed to play a dual role that combines the above characteristics due to a putative overlap in the substrate specificity of cytochrome P450 and drug resistance proteins. 40, 41 Nonetheless, this overlap in substrate specificity has not been shown to occur in all experimental systems. 42, 43 If the evaluation of drug-drug interactions is to be useful in planning better chemotherapy regimes, then a complete understanding of the effects of these interactions on the cellular and molecular processes of target cells will be essential. Toward achieving this goal, high-content profiling was developed as an automated platform on which experimental combinations of cells, drugs, and target activities could be analyzed in large arrays of easily interpretable data views. The resulting cellular response profiles to drugs or drug combinations provide a means to interrogate the precise orchestration of cellular processes that connect drugs with the numerous target activities they potentially alter.
EXPERIMENTAL PROCEDURES

Materials
Unless noted otherwise, materials were obtained from the following vendors. Ketoconazole, vinblastine, Triton X-100, mouse anti-α-tubulin (T9026), DMSO, Hoechst 33342, and collagen I were from Sigma Chemical Company (St. Louis, MO). Curacin A and 5-chloromethylfluorescein diacetate (CMFDA) were purchased from Molecular Probes, Inc. (Eugene, OR). Cell culture medium, fetal bovine serum, trypsin, and Hank's balanced salt solution (HBSS) were from Biowhittaker (Walkersville, MD), and methanol-free 16% formaldehyde solution was obtained from Polysciences, Inc. (Warrington, PA). The sheep anti-phospho-RSK90 (MAPKAP-k1A; T359) primary antibody was purchased from Upstate Biotechnology, Inc. (Lake Placid, NY); its characterization is described elsewhere, 44 and the labeled secondary antibodies were from Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA). 10% fetal bovine serum and added to the microplates (10 µL per well) using an automated liquid handling system (Biomek ® 2000; Beckman-Coulter, Inc., Fullerton, CA). When drug-drug interactions were measured, concentrated stocks of ketoconazole were added to the microplates containing cells and incubated at 37°C for 1 h before the addition of microtubule drugs. The cells were then incubated in the presence of both drugs for 14.5 h at 37°C in a humidified atmosphere at 5% CO 2 .
CMFDA labeling of cells
When a fluorescent cellular volume marker was required, the following procedure was used. CMFDA, a sulfhydryl reactive derivative of fluorescein, was dissolved immediately before use in dry DMSO at a concentration of 2 mM. Stock CMFDA solution (20 µL) was added to a 10-mL suspension of trypsinized cells in growth medium to give a final concentration of 4 µM. The cells plus CMFDA were incubated for 10 min at 37°C with occasional mixing. After labeling, the cell suspension was centrifuged, the cell pellet gently broken up, and the cells resuspended in 10 mL of fresh growth medium. The labeled cells were added to microplates and used in the same way as unlabeled cells.
Immunofluorescence labeling
At the end of an experiment, the solution was removed from the microplates and immediately replaced with a solution of HBSS containing 4% formaldehyde and 10 µg/ml Hoechst 33342 (40 µL/ well) to fix the cells and fluorescently label their nuclei. After incubation at room temperature for 20 to 30 min, the solution was removed from each well and replaced with HBSS (100 µL/well). At this point, microplates could be sealed and stored at 4°C overnight. The following reagent additions were then made to the microplates using the Biomek 2000. After removing the HBSS from each well, 0.5% (w/w) Triton X-100 was added (10 µL/well) and the plate incubated for 5 min at room temperature to detergent-extract a fraction of the soluble cellular components, including destabilized tubulin. The wells were then washed with HBSS (100 µL/well) followed by the addition of a primary antibody solution containing mouse anti-α-tubulin (1:4000) and sheep anti-phospho-RSK90 (1:400) in HBSS (10 µL/well). After a 1-h incubation at room temperature, the microplate wells were washed with HBSS as above, followed by the addition of a secondary antibody solution containing Cy5-labeled donkey antimouse (1:300) and Cy3-labeled donkey antisheep (1:300) antibodies diluted in HBSS (10 µL/well). After a 1-h incubation at room temperature, the microplate wells were washed as above and HBSS was added (100 µL/well) before sealing the microplates. Labeled microplates could be stored at 4°C for up to 2 weeks before high-content analysis.
High-content analysis
High-content analyses 45 of prepared microplates were performed with an ArrayScan ® HCS Reader (Cellomics, Inc., Pitts-burgh, PA). Briefly, the general screening application on the instrument was used to scan multiple optical fields, each with multiparameter fluorescence, within a subset of the wells of a 384well microplate. The application, using proprietary algorithms, produced more than 30 numerical feature values such as subcellular object intensities, shapes, and locations for each cell within an optical field. Some aspects of these proprietary algorithms have been described. 46 Depending on the experiment, 3 or 4 channels of fluorescence images were obtained for each of the 15 optical fields analyzed in each well. Contingent on the effect that the added chemical compounds had on the attachment of cells to the substrate, the total number of cells measured per well fell into the range of 450 to 1850, well above the number of cells required for statistically significant HCS measurements. [46] [47] [48] To build highcontent profiles of compound activity shown in the figures here, we imported the database of numerical values produced by the highcontent analysis into the S-Plus graphical and statistical program (Insightful, Inc., Seattle, WA).
RESULTS
Qualitative image analysis of tumor cells reveals that multiple organelle, cytoskeletal, and signaling targets are involved in microtubule drug action
The multiparameter images shown in Figure 1 demonstrate that the response of cellular targets was heterogeneous in that distinct phenotypes could be detected within a cell population. Although both drugs induced changes in nuclear condensation and RSK90 phosphorylation that mimic some aspects of normal mitosis, vinblastine and curacin A produced distinct microtubule cytoskeletal morphology changes. The phosphorylation level of RSK90 (T359), which was detected here with phosphospecific antibodies, was previously shown to be the same site phosphorylated by ERK both in vitro and in living cells. 44 Thus, the activation of 1 cellular stress pathway, which signaled through RSK90, could be measured as part of the high-content profiling system described here.
The first series of images ( Fig. 1A -D) shows that normalcycling cells contained mitotic cells (arrows) that simultaneously exhibited condensed nuclei and tubulin as well as phosphorylated RSK90. The second series ( Fig. 1E -H) indicates that 12.5 nM vinblastine produced a heterogeneous response within the population that contained condensed nuclei with occasional tripartite chromatin morphologies ( Fig. 1E , arrows) and an altered microtubule cytoskeleton accompanied by increased RSK90 phosphorylation in the same cells. As expected, vinblastine induced some microtubule aggregation at low concentrations and a marked net depolymerization of microtubules at higher concentrations (see below). The resulting solubilized tubulin protein was preferentially extracted during the permeabilization step of the immunofluorescence protocol (Fig. 1H ). The last series of images ( Fig. 1H -K) shows that 62.5 nM curacin A treatment also induced a heterogeneous response that included nuclear condensation, RSK90 phosphorylation, and unique tubulin morphology exhibited as a
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nuclear ring and cytoplasmic wisps. For both vinblastine and curacin A, it can be noted that nuclear condensation and RSK90 phosphorylation did not occur until the nuclei and remaining tubulin had maximally condensed, much as in the case of normal mitosis.
The heterogeneous response of tumor cell populations to drug action is addressed with high-content profiling
The complex response of cells to drugs requires multiparameter analysis with comparisons of these parameters at the single cell level. Furthermore, the heterogeneous response of single cells within a population (e.g., see Fig. 1 ) is an intrinsic property of biological systems and must be addressed by the analytical method.
High-content profiling has been developed to satisfy these fundamental strategic requirements. Figure 2 demonstrates how multiparameter image analysis data can be visualized in a way that addresses the population heterogeneity of cellular systems. The population density distribution, a mathematical approach to smoothing and normalizing histogram data so they can be represented graphically as a curve with unit area, allows facile detection of multiparameter cellular responses through shifts in peak height, number, and translation along an axis. 49 Furthermore, the fixed area of the fitted curve allows for better comparisons between pop- ulations of cells in which the total number of cells may differ due to cell plating or drug activity.
A ratiometric approach clarifies cellular responses involving overall changes in cell shape, intracellular fluorescent reagent distribution and intensity, or a mixture of all responses
Inherent within all epifluorescence-based assays of living and fixed cells is a component of the optical signal that is due to path length. 50 For example, a labeled cell may appear to be brighter in a rounded state than when it is well spread (e.g., upon cell rounding, more fluorescent material is moved into the light excitation volume, thus increasing the total fluorescence signal per unit area). Therefore, the normally heterogeneous distribution of cells within a population dictates that each population sample will contain a range of cellular physiological conditions, which includes morphology. High-content profiling was designed to enable dissection of the contributions due to cellular and subcellular morphological changes as well as changes in the distribution of fluorescent reagents. This approach was demonstrated for 2 parameters, nuclear condensation and RSK90 phosphorylation. Figure 3A ,B shows cellular fluorescence distribution data for cells treated with curacin A. The drug induced the formation of multiple populations of cells exhibiting ranges of RSK90 phosphorylation and nuclear condensation values. Because these cells were also labeled with CMFDA, a fluorescent reagent that, in this case, reports on only the pathlength component of the fluorescence signal, changes in morphology induced by curacin A could therefore be addressed through ratiometric analysis. Calculation of the ratio with the CMFDA value as the denominator for each cell before plotting the population density distribution showed that cells labeled for RSK90 phosphorylation produced a distribution containing at least 2 peaks ( Fig. 3C ). Thus, changes in the RSK90 P i value were consistent with a cellular response due mostly to increased RSK90 phosphorylation. Furthermore, the multiple peaks in the nuclear fluorescence signals in Figure 3B fused into 1 broad peak upon the same ratiometric analysis, consistent with the drug-induced changes measured for nuclear condensation being due mostly to changes in organelle shape and not to a gain or loss of chromatin.
Ketoconazole modulates the effect of microtubule drugs on multiple targets within HeLa cells
High-content profiling, which is essentially the extraction of multiparameter data from images, including those from Figure 1 was used to quantify the effect of ketoconazole on the cellular physiological responses to the 2 microtubule drugs. HeLa cells were treated with ketoconazole concentrations that varied across each row of the microplate. Vinblastine and curacin A were then added at concentrations that varied down each column. The data in Figures 4 and 5 show the population density distribution results of cross-titrations with respect to each of the cellular parameters measured. For example, the left-most column in Figure 4A (no ketoconazole) shows the effect of increasing vinblastine concentration on the microtubule cytoskeleton. The symmetrical distribution curve began to change shape at 3.1 nM vinblastine and continued to change through the highest concentration (100 nM), where it was apparent that net tubulin depolymerization had occurred (shift of the peak toward the left). On the other hand, the column of wells pretreated with 45 µM ketoconazole exhibited 2 distinct populations of cells at 3.1 nM vinblastine. As in the case of vinblastine, higher concentrations of curacin A induced a population of cells with net depolymerized tubulin, especially at the highest concentration of ketoconazole used (90 µM; Fig. 5 ). The stress pathway activation indicator, RSK90 phosphorylation ( Fig. 4-5 , red curves), and an organelle indicator, nuclear condensation ( Fig. 4-5 , black curves), were increased by microtubule drugs and potentiated by ketoconazole at the same concentration within the same cell populations. Nevertheless, the ability of ketoconazole to potentiate the destabilization of microtubules by vinblastine and curacin A was maximal at a concentration (90 µM) at which it also inhibited the capacity of vinblastine and curacin A to increase RSK90 P i and nuclear condensation values. This suggests that drug-drug interactions also have the potential to uncouple the net-work of cellular activities that all drugs have the potential to modulate.
The bimodal distributions of RSK90 phosphorylation values in populations of treated cells afforded a simple numerical evaluation. Figure 6 gives an example of how the population density distribution curves were converted to numerical values (RSK90 P i ratio). In this example, a threshold was set for the cellular distributions that essentially bisected the distribution into 2 differentially responding cell populations: one population containing cells with basal RSK90 phosphorylation values and a second population exhibiting elevated RSK90 phosphorylation values. The RSK90 P i ratio was calculated by dividing the number of cells above the threshold by the number of cells below the threshold. Figure 6 illustrates the value of normalization in cell populationbased assays. In this example, the control (untreated) well contained a total of 1615 cells, whereas the vinblastine-treated well contained about half that number, 843, due to the drug-induced loss of cells from the substrate. The RSK90 P i ratio, therefore, offers a way to correct the results from each well for the total cell number. Nevertheless, the cells lost from the substrate were likely those most sensitive to drug action. These "lost" cells induced an artificial drop in the RSK90 P i ratio at high drug concentrations.
The maximal effect of ketoconazole on a specific tumor cell type required that its concentration be precisely balanced with that of the microtubule drug
Mining the rich data set provided by high-content profiling in each experiment required new, easily interpretable techniques. Data visualization strategies that provided the ability to drill down into specific parameter sets were developed. The previously shown views of the data were consistent with ketoconazole having potentiating and inhibitory effects on the activity of microtubule drugs against multiple cellular targets. When the RSK90 P i ratio values were plotted as a function of microtubule drug concentration at the concentration of ketoconazole that had the greatest potentiating effect, a more detailed relationship between the activity of this antifungal drug and microtubule drug activity could be explored (Fig. 7) . For example, cross-titration data from HeLa cells treated with 45 µM ketoconazole showed that a vinblastine concentration near 1 nM provided the optimal complement in achieving the maximal response in HeLa and PC-3 cells (Fig. 7) . That plasma ketoconazole concentrations in human subjects can vary 2 orders of magnitude over a period of hours 51 implies that precise balancing of the cellular doses of microtubule drugs and ketoconazole is germane to a multidrug therapeutic approach.
Curacin A, at concentrations near 30 nM in HeLa cells, showed maximal activity when the cells were pretreated with ketoconazole ( Fig. 7B, solid circles) . The relatively muted response in the crosstitration data in PC-3 cells was consistent with ketoconazole being an inhibitory agent in these cells (Fig. 7B, solid triangles) .
The data presented thus far represent 1 time point in what is obviously a complex kinetic drug response. The treatment time, 14.5 h, was chosen as an optimum, based on maximizing responses for tubulin mass, RSK90 P i , and nuclear condensation values. Treatment times shorter than 10 h failed to show reproducible population shifts of all the measured parameters. At treatment times from 24 to 72 h, population density curves of each of the cellular parameters began returning to the same distributions seen in untreated cells. Treatment with drug concentrations spanning 3 orders of magnitude for 14.5 h resulted in the maximal differences in all high-content profiling parameters while minimizing cell loss from the substrate. This treatment regime, which permits drugs, cell types, and molecular targets to be combined in large analytical arrays, has been tested in other systems as well. For example, the time course presented here is similar for multiple tumor cell types, including A549 (small cell lung), NCI-H460 (large cell lung), MCF-7 and MDA-MB231 (breast), HCT-8 (colon), SHSY-5Y (neuroblastoma), and SNB-19 (glioblastoma) cells when treated with an array of other microtubule drugs as well, such as nocodazole, 2-methoxyestradiol, discodermolide, colchicine, and myoseverin (data not shown).
Multiparameter comparisons within populations of single cells reveal that target activities modulated by drug-drug interactions are complex and sensitive to small concentration changes
The data visualization strategy used in Figures 4 and 5 is a powerful tool for interpreting cell-based data at the population level, but it ignores the connections between the parameters at the singlecell level. Because each of the cells reported multiple activities, a data visualization strategy for creating parameter relationships within each cell was required. For example, the interaction of a stress pathway component (RSK90 phosphorylation) and a cytoskeletal component (tubulin mass) in the presence of 2 separate microtubule drugs plus ketoconazole is shown in Figure 8 . Figure 4 .
Here, the accompanying histograms are presented with the curves. Also indicated is the method by which 90 kDa ribosomal s6 kinase (RSK90) P i ratios were formed. First, a threshold was set in the distribution that separated the responding from the nonresponding populations. Then, an RSK90 P i ratio was formed by dividing the number of cells above the threshold by the number of cells below the threshold. concentrations of ketoconazole alone had on these 2 parameters (B11, B22). In these wells, cells in quadrants I and II (e.g., high RSK90 phosphorylation values) represented the native mitotic population that remained attached to the substrate, whereas cells in quadrants III and IV represented populations in all other phases of the cell cycle.
The second row of well-graphs in Figure 8 shows the effect of intermediate concentrations of vinblastine and curacin A in the absence or presence of a relatively high concentration of ketoconazole. Comparison of well-graphs I02 and I11 shows that ketoconazole potentiated the tubulin-aggregating activity of vinblastine by shifting the bulk of the population containing phosphorylated RSK90 to quadrant II. Curacin A, though, induced more heterogeneous RSK90 phosphorylation values with respect to tubulin mass values than did vinblastine (compare distributions in wells I02 and I13). Ketoconazole had less of a potentiating effect on the ability of curacin A to induce RSK90 phosphorylation than on vinblastine at the same concentration of ketoconazole (e.g., compare the distributions in quadrants I and II in wells I11 and I22).
The third row of well-graphs in Figure 8 shows the effects of relatively high concentrations of vinblastine and curacin A in the absence and presence of a relatively high concentration of ketoconazole. Well-graph M02 demonstrates that vinblastine induced some net depolymerization of microtubules compared to untreated cells (e.g., well B02), as indicated by the subtle shift of the cell population toward quadrants I and III. This well-graph also shows that 50 nM vinblastine induced a maximal amount of RSK90 phosphorylation by shifting a large proportion of the population toward higher RSK90 phosphorylation values (e.g., quadrants I and II). Ketoconazole considerably potentiated the activity of vinblastine at this concentration, as shown by the shift of most of the cell population to lower net microtubule depolymerization values (well M11; quadrants I and III). Finally, curacin A had a more homogeneous effect on the cell population at 500 nM than it did at 31 nM (e.g., compare the populations in quadrants I and II in wells I13 and N13). It can also be seen that those cells with the highest level of RSK90 phosphorylation were those that exhibited the most stabilized microtubule cytoskeleton (well N13; cell populations fell on 2 classes of diagonal lines). Finally, 45 µM ketoconazole had a relatively muted effect on the activity of curacin A compared to vinblastine activity at the same concentration (e.g., compare distributions of cells in wells M02 vs. M11 and N13 vs. N22).
To visualize similar cell population shifts due to drug-drug interactions but on the scale of an entire microplate, we prepared a color-coded dot plot ( Fig. 9 ). In the left panel, a diagonal-shaped band of warm-colored dots (green, yellow, and red) demonstrates the potentiating effect ketoconazole had on the ability of vinblastine to concomitantly activate the RSK90 pathway and modulate the microtubule cytoskeleton. The right panel of Figure 9 shows a more horizontally shaped band of warm colors indicative of the diminished ability of ketoconazole to potentiate the activity of curacin A. Nevertheless, ketoconazole at 90 µM strongly inhib-ited the stress pathway-inducing activities of both microtubule drugs. This high concentration of ketoconazole is, however, nearly an order of magnitude higher than the serum or plasma levels of the drug measured in human subjects. 51 
High-content profiling can be used to separate generalized toxicity and specific cell-killing effects
High-content profiling, as used here, provides physiological information on intact cells attached to a substrate. Thus, the total number of cells measured in a well provides an indication of toxicity that is a combination of drug-induced loss of cellular integrity with the loss of cell substrate adhesion. Figure 10 shows plots of the number of cells measured in each well at the microplate level. In the cases of vinblastine and curacin A, the toxicity of these 2 microtubule drugs dominated the toxicity induced by ketoconazole, even though it was used at much higher concentrations. Furthermore, combining these data with the data describing the specific effects of the drug combinations shown earlier provides a higher resolution description of the drug-drug interactions. For example, the most toxic combination of vinblastine and ketoconazole in HeLa cells occurred in a group of wells centered at 13 nM and 1.4 µM, respectively. This toxic combination contrasts with the peak of specific stress kinase activity induced by drugs when the same cell population was treated with 0.78 nM vinblastine and 45 µM ketoconazole ( Fig. 7) . Thus, the most toxic combination of drugs, as measured by loss of cell integrity and substrate adhesion, was not necessarily the combination that maximized the more specific physiological effects that are believed to lead to tumor cell killing.
DISCUSSION
Defining the cellular and molecular mechanisms of microtubule drug action with high-content profiling
The increasing number of reports demonstrating correlations between microtubule drug activity and the modulation of multiple cellular processes has set the stage for the development of new approaches to cellular analysis. The wide range of cell types, target activities, treatment strategies, measurement techniques, and combinations thereof make it difficult to compare results from different experiments performed independently to understand the molecular mechanisms involved in drug action in the clinical setting. There-fore, combinatorial cell biological approaches such as high-content profiling, which build large arrays of cellular data, can begin to amalgamate what on the surface appear to be disparate cellular data into a coherent network of chemical and molecular processes. For example, the cellular model system presented here, which did not require cell synchronization, further supports the hypothesis that microtubule drugs also activate MAPK pathways and connect the events of nuclear condensation, microtubule reorganization, and stress pathway activation. Furthermore, the 2 microtubule drugs tested, vinblastine and curacin A, had distinct morphological and concentration-dependent effects on the microtubule cytoskeleton but showed similar effects on nuclear condensation and stress pathway activation.
Dissecting the complex interplay of cells, targets, and interacting drugs
Work from multiple labs involving several cell types treated with various drug combinations has already demonstrated some synergistic and antagonistic interactions between microtubule drugs and other compounds. 33, 52 High-content profiling was used here to dissect the interaction of the classical antifungal drug ketoconazole with 2 microtubule drugs against 3 target activities within 2 cell types. This rapid combinatorial approach led to the Figure 8 was expanded to the microplate level using the following approach: (1) the cellular data were divided into quadrants as shown in Figure 8 , (2) the number of cells in quadrant II (cells with relatively highly phosphorylated 90 kDa ribosomal s6 kinase [RSK90] accompanied by stabilized or aggregated microtubules) was divided by the number of cells in quadrant III (cells with RSK90 phosphorylation and microtubule stability at or near control levels), and (3) these population ratio values were plotted as a function of drug concentration as color-coded dots with ratio values increasing on the yaxis, similar to a standard bar graph representation. To aid visualization, the dots were color-coded. Increasing population ratios were coded as blue < green < yellow < red. For example, the well treated with 25 nM vinblastine and 0 µM ketoconazole exhibited a maximal population shift toward cells containing highly phosphorylated RSK90 and highly stabilized or aggregated microtubules. . 10 . Cell integrity and substrate adhesion as measures of generalized drug toxicity. Given that an equal number of cells were plated in each well and that a fixed number of optical fields was measured in each well of the microplate, the total number of intact cells remaining attached to the substrate was indicative, in part, of the toxicity of the drug combinations used to treat the cells. To visualize cell population differences at the microplate level, a dot whose size represents the total number of HeLa cells measured in each well was plotted for the entire microplate. An increase in size of a single step represents an increase in total cell number measured per well of approximately 250 cells. Thus, relatively high concentrations of both vinblastine and curacin A caused cell loss from the substrate regardless of the ketoconazole concentration. Ketoconazole alone had minimal cytotoxicity for the examined dose range. conclusion that the ketoconazole and microtubule drug interactions occurred over relatively small concentration ranges near the plasma levels of ketoconazole attained in human subjects. 51 Moreover, these interactions had distinct effects regarding the cell type treated and the molecular and organellar target activities measured. Work done previously with PC-3 cells showed that ketoconazole had little or no potentiating effect when combined with paclitaxel or vinblastine. 33 It is interesting to note that high-content profiling revealed that ketoconazole was stronger in potentiating microtubule drug activity in cervical adenocarcinoma cells (HeLa) than in prostate adenocarcinoma cells (PC-3), despite the fact that ketoconazole has become associated with the treatment of prostate cancer. These results underscore the need to understand the full range of cellular processes that ketoconazole influences and how it can be advantageously combined with other drugs to potentially minimize side effects while maximizing efficacy.
High-content profiling as a platform for lead optimization and chemotherapeutic strategy
That cells are the ultimate targets of drug activity intimates a cell-centric approach for drug discovery whereby cells are used as living reporters of the chemical and molecular activities of potential lead compounds. High-content profiling, a combinatorial application of high-content screening, 45 was developed to conduct parallel cellular studies that maximize the relevant information extracted from the simultaneous measurement of ionic, metabolic, macromolecular, and organellar interrelationships that drugs potentially modulate. The data presented in this report represent only a fraction of the total database built from recorded features from the multiple measurements obtained in each experiment. Thus, inherent within high-content profiling is the ability of the user to move between high-level views of the data (e.g., plate graphs of multiparameter data), multiple levels of intermediate complexity, and cellular and subcellular images and image-derived data.
In a broader sense, high-content profiling is an effective approach to address the intrinsic heterogeneity driving the life processes that comprise living cells. By visualizing and quantifying the interrelationships between these processes and the effect drugs have on them, the important aspects of cellular heterogeneity become a rich source of information on how cells respond at the chemical and molecular levels in time and space to compound treatment.
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